Vireo Growth Inc. splits its revenue into 2 lines in its filings. The largest line in fiscal 2025, which ended Dec 31, 2025 was Retail at $219.9 million, 82% of the total.
USD in millions. The percent under a figure is the change from the year before.
| Line |
FY 2026
Jun 30, 2026
|
FY 2025
Dec 31, 2025
|
FY 2024
Dec 31, 2024
|
FY 2023
Dec 31, 2023
|
FY 2022
Dec 31, 2022
|
FY 2021
Dec 31, 2021
|
|---|---|---|---|---|---|---|
| Revenue |
512
|
269
|
99
|
88
|
75
|
54
|
| Retail |
408
+328.9%
share 79.7%
|
220
+176.5%
share 81.8%
|
80
+8.0%
share 80.0%
|
74
+18.5%
share 83.5%
|
62
+39.0%
share 83.2%
|
45
share 82.1%
|
| Wholesale Product |
70
+153.8%
share 13.7%
|
49
+146.0%
share 18.2%
|
20
+36.8%
share 20.0%
|
15
+16.1%
share 16.5%
|
13
+28.2%
share 16.8%
|
10
share 17.9%
|
How these figures are calculated
Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- VREOF (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- British Columbia, Canada
- Headquarters
- Minneapolis, MN
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1771706
- Former names
- Goodness Growth Holdings, Inc. (until Jun 24, 2024); Vireo Health International, Inc. (until May 14, 2021)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.